TMDX logo

TransMedics Group Stock Price

Symbol: NasdaqGM:TMDXMarket Cap: US$4.1bCategory: Healthcare

TMDX Share Price Performance

US$128.50
-19.95 (-13.44%)
24.4% undervalued intrinsic discount
US$170.00
Fair Value
US$128.50
-19.95 (-13.44%)
24.4% undervalued intrinsic discount
US$170.00
Fair Value
Price US$128.50
AnalystHighTarget US$170.00
AnalystConsensusTarget US$140.57
AnalystLowTarget US$80.00

TMDX Community Narratives

AN
AnalystHighTarget
AnalystHighTarget·Updated
Fair Value US$170.00 24.4% undervalued intrinsic discount

Aging Population And Medical Technology Advances Will Expand Transplant Markets

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget·Updated
Fair Value US$140.57 8.6% undervalued intrinsic discount

Next-Gen Heart And Lung Programs Will Drive Deeper Market Adoption In 2025

2users have liked this narrative
0users have commented on this narrative
50users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget·Updated
Fair Value US$80.00 60.6% overvalued intrinsic discount

FDA Trials And Logistics Expansion Will Spark Mixed Outcomes

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

TMDX Community Fair Values

Recent TMDX News & Updates

No updates

TransMedics Group, Inc. Key Details

US$531.3m

Revenue

US$213.6m

Cost of Revenue

US$317.7m

Gross Profit

US$246.0m

Other Expenses

US$71.7m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
2.10
Gross Margin
59.79%
Net Profit Margin
13.49%
Debt/Equity Ratio
160.6%

TransMedics Group, Inc. Competitors

 
 
 
 
 
 
 
 
 
 
 
 

About TMDX

Founded
1998
Employees
728
CEO
Waleed Hassanein
WebsiteView website
www.transmedics.com

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

U.S. Market Performance

  • 7 Days: -1.2%
  • 3 Months: 13.1%
  • 1 Year: 22.8%
  • Year to Date: 7.3%
Over the last 7 days, the market has dropped 1.2%, driven by a loss of 4.7% in the Consumer Discretionary sector. In contrast to the last week, the market is actually up 23% over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading